Endometrial cancer prognosis in women with endometriosis and adenomyosis. A retrospective nationwide cohort study of 40,840 women.

Marjolein Hermens MD, Anne M van Altena MD PhD, Maaike van der Aa PhD, Johan Bulten MD PhD, Huib AAM van Vliet MD PhD, Albert G Siebers PhD, Ruud LM Bekkers MD PhD

Supplemental material table of contents

Supplemental table 1          page 2
Supplemental table 2          page 3
Supplemental figure 1         page 4
Supplemental figure 2         page 5
## Supplemental table 1 Baseline characteristics for patients included in the Cox proportional hazard analysis.

|                              | Endometriosis (n=294) | Adenomyosis (n=1,125) | Endometriosis and adenomyosis (n=138) | No endometriosis or adenomyosis (n=33,985) |
|------------------------------|-----------------------|-----------------------|----------------------------------------|--------------------------------------------|
| **Age at endometrial cancer diagnosis in years (IQR)a** | 60 (IQR 53-68) | 62 (IQR 55-70) | 57 (IQR 52-65) | 66 (IQR 59-75) |
| **Year of diagnosis (IQR)b** | 2004 (IQR 1997-2010) | 2004 (IQR 1996-2009) | 2004 (IQR 1997-2010) | 2004 (IQR 1997-2010) |
| **Endometrial cancer stagea** | | | | |
| Stage 1                      | 240 (81.6%)          | 1,033 (91.8%)        | 117 (84.8%)               | 26,693 (78.5%)               |
| Stage 2                      | 27 (9.2%)            | 43 (3.8%)            | 9 (6.5%)                  | 2,791 (8.2%)                |
| Stage 3                      | 18 (6.1%)            | 41 (3.6%)            | 10 (7.2%)                 | 2,909 (8.6%)                |
| Stage 4                      | 9 (3.1%)             | 8 (0.7%)             | 2 (1.4%)                  | 1,592 (4.7%)                |
| **Histological tumor typea** | | | | |
| Endometrioid                 | 170 (57.8%)          | 610 (54.2%)          | 76 (55.1%)                | 18,599 (54.7%)              |
| Clear cell                   | 0 (0.0%)             | 10 (0.9%)            | 0 (0.0%)                  | 482 (1.4%)                  |
| Serous                       | 6 (2.0%)             | 13 (1.2%)            | 0 (0.0%)                  | 951 (2.8%)                  |
| Mucinous                     | 5 (1.7%)             | 8 (0.7%)             | 1 (0.7%)                  | 286 (0.8%)                  |
| Adenocarcinoma NOS           | 113 (38.4%)          | 484 (43.0%)          | 61 (44.2%)                | 13,668 (40.2%)              |
| **Histological gradinga**    | | | | |
| Low                          | 156 (53.1%)          | 657 (58.4%)          | 92 (66.7%)                | 15,035 (44.2%)              |
| Intermediate                 | 90 (30.6%)           | 335 (29.8%)          | 39 (28.3%)                | 12,098 (35.6%)              |
| High                         | 48 (16.3%)           | 133 (11.8%)          | 7 (5.1%)                  | 6,714 (19.8%)               |
| **Surgerya**                 | | | | |
| Yes                          | 282 (95.9%)          | 1,119 (99.5%)        | 137 (99.3%)               | 32,532 (95.7%)              |
| No                           | 12 (4.1%)            | 6 (0.5%)             | 1 (0.7%)                  | 1,453 (4.3%)                |
| **Chemotherapya**            | | | | |
| Yes                          | 15 (5.1%)            | 15 (1.3%)            | 4 (2.9%)                  | 1,128 (3.3%)                |
| No                           | 279 (94.9%)          | 1,110 (98.7%)        | 134 (97.1%)               | 32,857 (96.7%)              |
| **Vital status as of January 31, 2020a** | | | | |
| Alive                        | 175 (59.5%)          | 664 (59.0%)          | 96 (69.6%)                | 16,424 (48.3%)              |
| Passed away                  | 119 (40.5%)          | 461 (41.0%)          | 42 (30.4%)                | 17,561 (51.7%)              |

Data are in numbers (percentage) unless otherwise specified. IQR = interquartile range, NOS= Not Otherwise Specified

- p<0.005 for comparison between patients with endometrial cancer with histological proven endometriosis and /or adenomyosis and those without.
- p value not statistically significant for comparison between patients with endometrial cancer with histological proven endometriosis and / or adenomyosis and those without.
Supplemental table 2 Hazard ratios of overall survival among women with endometrial cancer in univariable and multivariable analysis (n=35,542).

|                        | Univariable analysis | Multivariable analysis |
|------------------------|----------------------|------------------------|
|                        | Hazard Ratio (95%CI) | Hazard Ratio (95%CI)   |
| Endometriosis/adenomyosis | 0.63 (0.59-0.69)b    | 0.98 (0.90-1.06)c      |
| Age                    | 1.09 (1.08-1.09)b    | 1.08 (1.08-1.08)b      |
| **Endometrial cancer stage** |                      |                        |
| Stage 1                | 1.00 (ref)           | 1.00 (ref)             |
| Stage 2                | 1.64 (1.56-1.72)b    | 1.40 (1.33-1.47)b      |
| Stage 3                | 2.69 (2.57-2.81)b    | 2.31 (2.20-2.42)b      |
| Stage 4                | 7.38 (6.98-7.80)b    | 4.23 (3.95-4.52)b      |
| **Histological tumor type** |                      |                        |
| Endometrioid           | 1.00 (ref)           | 1.00 (ref)             |
| Clear cell             | 2.12 (1.91-2.37)b    | 1.10 (0.98-1.23)b      |
| Serous                 | 3.13 (2.89-3.38)b    | 1.25 (1.14-1.36)b      |
| Mucinous               | 1.28 (1.10-1.48)b    | 1.04 (0.90-1.21)b      |
| Adenocarcinoma NOS     | 1.29 (1.25-1.33)b    | 1.20 (1.16-1.24)b      |
| **Histological grading** |                      |                        |
| Low                    | 1.00 (ref)           | 1.00 (ref)             |
| Intermediate           | 1.48 (1.43-1.53)b    | 1.21 (1.17-1.25)b      |
| High                   | 2.65 (2.56-2.76)b    | 1.71 (1.64-1.78)b      |
| Surgery                | 0.14 (0.13-0.15)b    | 0.39 (0.36-0.41)b      |
| Chemotherapy           | 2.56 (2.39-2.75)b    | 1.22 (1.12-1.32)b      |

Only significant factors in univariable analysis are displayed.
NOS = not otherwise specified.
*p-value < 0.0005 for categorical factor in univariable and multivariable analyses. bp-value<0.0005. *p-value not statistically significant.
Supplemental figure 1 Kaplan-Meier curve of overall survival, by endometriosis/adenomyosis status (binary).
Supplemental figure 2 Kaplan-Meier curve of overall survival, by endometriosis/adenomyosis status (binary) per low/high stage disease and histological subtype.